WHO issues warning for growing resistance to HIV drug of GSK
The World Health Organization (WHO) has said resistance to GSK's HIV drug dolutegravir has exceeded levels observed during its trials, citing observational and survey data received from a few countries.Resistance ranged from 3.9% to 8.6% and reached 19.6% among people who have received and transitioned to a dolutegravir-containing antiretroviral therapy (ART) regimen to combat high HIV...
Login or Register to read the full article
The World Health Organization (WHO) has said resistance to GSK's HIV drug dolutegravir has exceeded levels observed during its trials, citing observational and survey data received from a few countries.
Resistance ranged from 3.9% to 8.6% and reached 19.6% among people who have received and transitioned to a dolutegravir-containing antiretroviral therapy (ART) regimen to combat high HIV viral loads.
For more information click on the link below:
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd